Instylla, Inc. announced that it recently submitted the final module of its premarket approval (PMA) application to the FDA ...

Financial Results for the Fourth Quarter Ended December 31, 2024 For the fourth quarter of 2024, total revenue increased by $188,000, or 10.7%, to $1,949,000, from $1,761,000 during the fourth quarter ...

Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) ...